OTCMKTS:PKTX ProtoKinetix (PKTX) Stock Price, News & Analysis $0.01 +0.00 (+2.04%) (As of 12/31/2024 05:38 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort Interest About ProtoKinetix Stock (OTCMKTS:PKTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProtoKinetix alerts:Sign Up Key Stats Today's Range$0.01▼$0.0150-Day Range$0.0081▼$0.012552-Week Range$0.01▼$0.02Volume2,521 shsAverage Volume120,575 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.Read More… ProtoKinetix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks10th Percentile Overall ScorePKTX MarketRank™: ProtoKinetix scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ProtoKinetix. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ProtoKinetix is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProtoKinetix is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverProtoKinetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProtoKinetix has recently decreased by 70.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtoKinetix does not currently pay a dividend.Dividend GrowthProtoKinetix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverProtoKinetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProtoKinetix has recently decreased by 70.65%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentProtoKinetix has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ProtoKinetix this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProtoKinetix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.87% of the stock of ProtoKinetix is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of ProtoKinetix is held by institutions.Read more about ProtoKinetix's insider trading history. Receive PKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProtoKinetix and its competitors with MarketBeat's FREE daily newsletter. Email Address PKTX Stock News HeadlinesFNAM Evolutionary Genomics, Inc.July 30, 2024 | seekingalpha.comSLLAX SEI Institutional Managed Trust Small Cap Fund InstJuly 25, 2024 | seekingalpha.comElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation.January 1, 2025 | Brownstone Research (Ad)ProtoKinetix, Incorporated (PKTX) Stock Price, News, Quote & History - Yahoo FinanceMay 25, 2024 | finance.yahoo.comNauticus Robotics And 2 Other Stocks Under $3 Insiders Are BuyingApril 16, 2024 | markets.businessinsider.comProtoKinetix, Incorporated (PKTX)November 18, 2023 | finance.yahoo.comProtoKinetix Inc PKTXNovember 12, 2023 | morningstar.comInsiders Buying ProtoKinetix And 2 Other Stocks Under $2October 30, 2023 | benzinga.comSee More Headlines PKTX Stock Analysis - Frequently Asked Questions How do I buy shares of ProtoKinetix? Shares of PKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ProtoKinetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProtoKinetix investors own include Sangamo Therapeutics (SGMO), Abrdn Asia-Pacific Income Fund (FAX), MSP Recovery (LIFW), MSP Recovery (LIFW), Fulcrum Therapeutics (FULC), NVIDIA (NVDA) and Tenax Therapeutics (TENX). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PKTX Previous SymbolNASDAQ:PKTX CUSIPN/A CIK1128189 Webwww.protokinetix.com Phone(330) 445-4971FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:PKTX) was last updated on 1/1/2025 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredTarget More Reliable Returns in 2025[LIVE] How the Pros are Trading Options in 2025 Charles Payne reveals beginner-friendly options strategies ...Unstoppable Prosperity | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProtoKinetix, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share ProtoKinetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.